David Bharucha sold $158k of MIST
Chief Medical Officer at Milestone Pharmaceuticals Inc.. 70,252 shares at an average of $2.25, traded Dec 15, 2025, filed Jan 28, 2026.
Score components
- +15RoleOfficer
- +11Trade size$158k at market
- +10Share of holdings soldSold 43% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -11.9%, 3m -6.2%, 6m -46.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001910985-26-000003, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 12, 2025 | AGrant or award Common Shares | +100,000 | - | - | 163,333 | Jan 28, 2026 |
| Dec 15, 2025 | SOpen-market sale Common Shares | -58,007 | $2.32 | $135k | 105,326 | Jan 28, 2026 |
| Jan 26, 2026 | MOption exercise Common Shares | +20,100 | - | - | 125,426 | Jan 28, 2026 |
| Jan 26, 2026 | SOpen-market sale Common Shares | -12,245 | $1.93 | $24k | 113,181 | Jan 28, 2026 |
| Dec 12, 2025 | AGrant or award Employee Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jan 28, 2026 |
| Jan 26, 2026 | MOption exercise Restricted Stock Unitsderivative | -20,100 | $0.00 | $0 | 60,300 | Jan 28, 2026 |
Related signals
Other insiders at Milestone Pharmaceuticals Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 14Weak | Milestone Pharmaceuticals Inc. | Joseph Oliveto President and CEO | $82k 36,500 shares | -8% | |
| 43Moderate | Milestone Pharmaceuticals Inc. | Amit Hasija CFO & EVP of Corp. Development | $158k 70,252 shares | -47% | |
| 51Moderate | Milestone Pharmaceuticals Inc. | Joseph Oliveto President and CEO | $375k 167,577 shares | -29% | |
| 36Weak | Milestone Pharmaceuticals Inc. | Lorenz Muller Chief Commercial Officer | $146k 64,746 shares | -26% | |
| 51Moderate | Milestone Pharmaceuticals Inc. | Jeffrey Edward Nelson Chief Operating Officer | $158k 70,252 shares | -70% | |
| 20Weak | Milestone Pharmaceuticals Inc. | Joseph Oliveto President and CEO | $98k 43,500 shares | -13% | |
| 37Weak | MISTbuy Milestone Pharmaceuticals Inc. | David Bharucha Chief Medical Officer | $47k 10,000 shares | - | |
| 54Moderate | Milestone Pharmaceuticals Inc. | Debra K. Liebert director | $74k 14,000 shares | - | |
| 55Moderate | Milestone Pharmaceuticals Inc. | Michael John Tomsicek director | $80k 15,000 shares | - | |
| 53Moderate | Milestone Pharmaceuticals Inc. | Richard C Pasternak director | $52k 10,000 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.